

boiling 10% HCl (foaming). After refluxing for 1 hr, the solution was cooled, diluted with 100 ml of H₂O, and filtered hot. The oil which separated on addition of excess 10 N NaOH to the cold filtrate was extracted with PhH, and the combined extracts were washed with H₂O, dried, and evaporated. Treatment of the oily residue with ethanolic HCl gave, after 2 days, 9.0 g (87%) of crystalline product: mp 217–220°. Recrystallization from 95% EtOH–Et₂O provided 5.0 g (48%): mp 225–228°. Constant melting material was obtained by two additional recrystallizations: mp 234–235°; ir 2780–2550 (NH₃⁺), 2100 (NH₃⁺), 1613 and 1563 (NH₃⁺ and aromatic), and 1517 cm⁻¹ (aromatic). Anal. (C₂₆H₄₂Cl₂N₂O₄) C, H, N.

References and Notes

- (1) (a) Publication No. 103. (b) Subsidiary of E. I. du Pont de Nemours & Co., Inc., Wilmington, Del.
- (2) (a) L. J. Fliedner, Jr., J. M. Schor, M. J. Myers, and I. J. Pachter, *J. Med. Chem.*, **14**, 580 (1971); (b) L. J. Fliedner, Jr., M. J. Myers, J. M. Schor, and I. J. Pachter, *ibid.*, **16**, 749 (1973).
- (3) R. L. Buchanan, V. Sprancmanis, T. A. Jenks, R. R. Crenshaw, G. M. Luke, H. M. Holava, and R. A. Partyka, *J. Med. Chem.*, **17**, 1241 (1974); R. L. Buchanan, V. Sprancmanis, T. A. Jenks, R. R. Crenshaw, and G. M. Luke, *ibid.*, **17**, 1248 (1974); F. Markwardt, H. P. Klocking, J. Hauptmann, and G. Faust, *Thromb. Res.*, **2**, 383 (1973); R. L. Cavanagh, H. Imanishi, J. D. Bibbens, C. H. Taylor, D. S. Moylan, and J. P. Buyniski, *ibid.*, **5**, 633 (1974).
- (4) Y. Kanaoka, E. Sato, O. Yonemitsu, and Y. Ban, *Tetrahedron Lett.*, 2419 (1964).
- (5) G. Hahn and H. F. Gudjons, *Ber.*, **71B**, 2175 (1938).
- (6) (a) D. Papa, E. Schwenk, and H. Hankin, *J. Am. Chem. Soc.*, **69**, 3018 (1947); (b) W. J. Houlihan and R. E. Manning, U.S. Patent 3502679 (1970).
- (7) G. Rembarz and M. Schwill, *J. Prakt. Chem.*, **31**, 127 (1966).
- (8) J. M. Schor, Ed., "Chemical Control of Fibrinolysis-Thrombolysis", Wiley, New York, N.Y., 1970, p 113.
- (9) M. A. Karim, W. H. Linnell, and L. K. Sharp, *J. Pharm. Pharmacol.*, **12**, 82 (1960).
- (10) R. A. Abramovitch and D. Shapiro, *J. Chem. Soc.*, 4589 (1956).
- (11) F. C. Pennington, W. D. Celmer, W. M. Mc Lamore, V. V. Bogert, and I. A. Solomons, *J. Am. Chem. Soc.*, **75**, 109 (1953).
- (12) Y. Sumiki and S. Tamura, Japan Patent 9066 (1955); *Chem. Abstr.*, **52**, 1239b (1958).
- (13) D. Cobern, J. S. Hobbs, R. A. Lucas, and D. J. Mackenzie, *J. Chem. Soc. C*, 1897 (1966).
- (14) O. Gisvold, D. Buelow, and E. H. Carlson, *J. Am. Pharm. Assoc.*, **35**, 188 (1946).

Basic Derivatives of 6,7-Dihydroindolo[1,7-*ab*][1]benzazepine and 6*H*-Indolo[7,1-*cd*][1,5]benzoxazepine as Potential Antidepressant Agents

Luciano Toscano,* Giampiero Grisanti, Giuseppe Fioriello, Ennio Seghetti,


Department of Synthetic Chemical Research

Alberto Bianchetti, Giuseppe Bossoni, and Mario Riva

Department of Pharmacology, Pierrel S.p.A. Research Laboratories, 20121 Milan, Italy. Received June 16, 1975

Basic derivatives of 6,7-dihydroindolo[1,7-*ab*][1]benzazepine and 6*H*-indolo[7,1-*cd*][1,5]benzoxazepine incorporating the imipramine basic side chain were synthesized and screened for antidepressant activity in mice. With few exceptions, the compounds unsubstituted at C-2 antagonized reserpine-induced ptosis and hypothermia showing negligible anticholinergic and antihistaminic properties. The compound 1-[2-(*N*-methyl-*N*-benzylamino)ethyl]-6,7-dihydroindolo[1,7-*ab*][1]benzazepine had the highest toxicity-activity ratio.


In studies of imipramine-like antidepressants, some compounds incorporating the main structural features of imipramine were investigated.¹ The imipramine basic side chain was also incorporated into 6,7-dihydroindolo[1,7-*ab*][1]benzazepine (I), but the resulting compounds all substituted at C-2 did not show imipramine-like activity in the usual pharmacological tests.² Continuing along this line, 3-methyl-1,2,3,4,8,9-hexahydropyrido[4',3':2,3]-indolo[1,7-*ab*][1]benzazepine (II) was also synthesized³ and was claimed to have powerful antiserotonin activity but was devoid of antidepressant activity. It occurred to us that the alkyl substituents at C-2 could be responsible for the absence of activity, either by steric hindrance in drug-receptor interaction or by preventing the formation of some active metabolites. Therefore, novel *N*-substituted 1-(2-aminoethyl)-6,7-dihydroindolo[1,7-*ab*][1]benzazepines (Table IV, 28–31), unsubstituted at C-2, were synthesized and evaluated for antidepressant activity. Since the initial pharmacological results were positive, we have synthesized several other compounds including some basic derivatives of 6*H*-indolo[7,1-*cd*][1,5]benzoxazepine



(III), in order to gain further insight into the structure-activity relationships.

Chemistry. The synthesis of all the compounds reported in Table IV begins with the preparation of 5–13 as

Scheme I



outlined in Scheme I. Compound 4 was prepared according to the procedure of Cattanaach et al.² A similar synthetic approach was suitable for the preparation of 5-amino-5,11-dihydrodibenz[b,e][1,4]oxazepine (3). The starting material 5,11-dihydrodibenz[b,e][1,4]oxazepine⁴ (1) was treated with powdered sodium nitrite in dimethylformamide to yield 2.


The next reduction of *N*-nitroso compound 2 with zinc dust and acetic acid⁵ gave the desired hydrazine, which was converted to its hydrochloride 3. Condensation of 3 and 4 with suitable keto compounds (Table I) gave hydrazones which without isolation cyclized (Fischer cyclization) to 5-13 in ethanolic hydrogen chloride.²

Compound 4 with ethyl 4-phenylacetoacetate was converted to a mixture of 11 and 12. The two isomers were shown by NMR and GC to be present in a 1:1 ratio and separated by column chromatography on alumina. In the same manner 3 reacted with ethyl pyruvate affording a mixture of 6 and 13 isomers present in a 4:1 ratio by NMR and separated as above. In contrast reaction of 3 with 2-butanone gave only 8.


The structures of 6, 8, and 11-13 were assigned from their NMR spectra. Comparison of the NMR spectra of 11 and 12 showed that only in the 1-phenyl isomer the C-10 and C-11 protons were relatively shielded, as expected⁶ on the basis of the structure of the isomers. When the NMR spectra of the two isomers, derived from 3 and ethyl pyruvate, were compared to the spectrum of 5, it was found that the C-3 proton in only one isomer and in 5 showed a similar downfield one-proton quartet centered at δ 7.55 ($J = 7$ and 3 Hz) attributable to the deshielding influence of the indolic double bond.⁷ In contrast, the C-3 proton in the other isomer shifted to higher field ($\Delta\delta$ 15 ppm) than the corresponding proton in 5. Since it has been recognized⁸ that the methoxy substituent causes significant shielding on the aromatic protons, the structure 13 was assigned to the isomer which showed the C-3 proton quartet centered at δ 7.40 ($J = 7$ and 3 Hz). Accordingly, the structure 8 was assigned to the single product obtained by cyclization of 3 with 2-butanone in ethanolic hydrogen chloride since its NMR spectrum presented a similar downfield C-3 proton quartet of 7.

Hydrolysis of 5 and following decarboxylation of the acid

Scheme II



Scheme III



15, according to a procedure previously described,² resulted in the formation of the 6,7-dihydroindolo[1,7-*ab*][1]-benzazepine (14).

Compounds 27-30 of Table IV were prepared as shown in Scheme II. The synthesis involved formation of the acid chlorides from 5 and 6 and their reaction with diazomethane to yield the diazo ketones 18 and 19 (Table II). Photochemical Wolff rearrangement⁹ of the last in the presence of an excess of secondary amines yielded the corresponding amides 20-23 (Table III) which, upon reduction with lithium aluminum hydride in refluxing ethyl ether, yielded the basic derivatives 27-30.

In order to obtain 26, 32, 33, and 37-39 of Table IV the tetracyclic compounds 7-10 and 14 were subjected to Mannich reaction^{7,10} as outlined in Scheme III. Condensation of 7 and 8 with formaldehyde and dimethylamine occurred on the C-1 methyl group,¹¹ yielding 32 and 26, respectively. Treatment of 8 with formaldehyde and *N*-methyl-*N*-benzylamine gave 33. No substitution on the methyl group was observed under these conditions for 9. Mannich condensation^{2,12} of 9, 10, and 14 with formaldehyde and dimethylamine occurred on C-2 to give 37-39. Compounds 31 and 34 of Table IV were obtained by catalytic debenzoylation² of 29 and 33.

Table I. Fischer Cyclization Compounds^a

No.	X	Y	Z	Condensing keto compound	Re-flux time, hr	Formula	Yield, % ^b	Mp, °C	Crystn solvent ^c	Analyses ^d
5	CH ₂ -CH ₂	H	COOEt	MeCOCOEt	4	C ₁₉ H ₁₇ NO ₂	50	94-96 ^{e,f}	P	C, H, N
6	O-CH ₂	H	COOEt	MeCOCOEt	1	C ₁₈ H ₁₅ NO ₃	35	76-78	P	C, H, N
7	CH ₂ -CH ₂	Me	Me	MeCOEt	1	C ₁₈ H ₁₇ N	42	84-86 ^g	A	C, H, N
8	O-CH ₂	Me	Me	MeCOEt	0.5	C ₁₇ H ₁₅ NO	65	135-137 ^h	A	C, H, N
9	CH ₂ -CH ₂	H	Me	MeCOMe	4	C ₁₇ H ₁₅ N	23	91-93 ⁱ	M	C, H, N
10	CH ₂ -CH ₂	H	Ph	PhCOMe	1	C ₂₂ H ₁₇ N	22	166-167	E	C, H, N
11	CH ₂ -CH ₂	Ph	CH ₂ COOEt	PhCH ₂ CO-CH ₂ COOEt	5	C ₂₆ H ₂₃ NO ₂	12 ^j	k		
12	CH ₂ -CH ₂	CH ₂ COOEt	Ph	PhCH ₂ CO-CH ₂ COOEt	5	C ₂₆ H ₂₃ NO ₂	16 ^j	169-170 ^l	E	C, H, N
13	CH ₂ -O	H	COOEt	MeCOCOEt	1	C ₁₈ H ₁₅ NO ₃	10	125-127	P	C, H, N
14	CH ₂ -CH ₂	H	H			C ₁₆ H ₁₃ N	79	99-101 ^m	E	C, H, N

^a All samples were obtained by refluxing 3 or 4 with suitable keto compounds in ethanolic HCl, except 14 which was obtained from 5 as previously described.² ^b No attempts were made to optimize yields. ^c P, petroleum ether; A, Me₂CO; M, MeOH; E, EtOH. ^d Analyses for elements were within ±0.4% of the theoretical values. ^e Lit.² mp 90-92°. ^f NMR δ 7.55 (dd, 1, *J* = 7 and 3 Hz, H-3) and 7.45 (s, 1, H-2). ^g NMR δ 7.35 (dd, 1, *J* = 7 and 3 Hz, H-3), 2.45 (s, 3, CH₃-1), and 2.30 (s, 3, CH₃-2). ^h NMR δ 7.35 (dd, 1, *J* = 7 and 3 Hz, H-3), 5.25 (s, 2, OCH₂), 2.45 (s, 3, CH₃-1), and 2.30 (s, 3, CH₃-2). ⁱ NMR δ 6.45 (q, 1, *J* = 1 Hz, H-2) and 2.50 (d, 3, *J* = 1 Hz, CH₃). ^j Yield given for the chromatographic isolation on alumina. ^k Sample not crystallized; NMR δ 7.70-6.95 (m, 12, Ar H) and 4.77 (s, 2, CH₂CO); ir 1740 cm⁻¹ (ester C=O). ^l NMR δ 7.70-6.40 (m, 12, Ar H) and 4.72 (s, 2, COCH₂); ir 1740 cm⁻¹ (ester C=O); AlLiH₄ reduction of a sample afforded 2-(2-hydroxyethyl)-6,7-dihydro-1-phenylindolo[1,7-*ab*][1]benzazepine: mp 168-170° (C₆H₆-petroleum ether); NMR δ 3.95 (t, 2, *J* = 6 Hz, CH₂CH₂O) and 3.50-2.95 (m, 6, seven-membered ring H and CH₂CH₂O) after addition of D₂O. Anal. (C₂₄H₂₁NO) C, H, N. ^m Lit.² mp 96-97°.

Table II. Acids 15-17 and Diazo Ketones 18 and 19

15-17

18, 19

No.	X	Y	n	Formula	Yield, % ^a	Mp, °C	Crystn solvent ^b	Analyses ^c
15	CH ₂ -CH ₂	H	0	C ₁₇ H ₁₃ NO ₂	89	218-220 ^{d,e}	E-W	C, H, N
16	O-CH ₂	H	0	C ₁₆ H ₁₁ NO ₃	91	232-234 ^{d,f}		
17	CH ₂ -CH ₂	Ph	1	C ₂₄ H ₁₉ NO ₂	66	192-194 ^d	B-P	C, H, N
18	CH ₂ -CH ₂			C ₁₈ H ₁₃ N ₃ O	88	119-121 ^f		
19	O-CH ₂			C ₁₇ H ₁₁ N ₃ O ₂	g			




^a No attempts were made to optimize yields. ^b E, EtOH; W, H₂O; B, C₆H₆; P, petroleum ether. ^c Analyses for elements were within ±0.4% of the theoretical values. ^d Decomposed. ^e Lit.² mp 221-223° dec. ^f Melting point was determined on the crude product. ^g Isolated in 84% yield on Florisil column and not crystallized.

Table III. Amides

No.	X	Y	n	R ₁	R ₂	Formula	Yield, % ^a	Mp, °C	Crystn solvent ^b	Analyses ^c
20	CH ₂ -CH ₂	H	1	Me	Me	C ₂₀ H ₂₀ N ₂ O	58 ^d	e		
21	O-CH ₂	H	1	Me	Me	C ₁₉ H ₁₈ N ₂ O ₂	61 ^d	e		
22	CH ₂ -CH ₂	H	1	Me	PhCH ₂	C ₂₆ H ₂₄ N ₂ O	39 ^d	e		
23	CH ₂ -CH ₂	H	1	PhCH ₂	PhCH ₂	C ₃₂ H ₂₈ N ₂ O	53 ^d	e		
24	CH ₂ -CH ₂	H	0	Me	Me	C ₁₉ H ₁₈ N ₂ O	96 ^d	e		
25	CH ₂ -CH ₂	Ph	1	Me	Me	C ₂₆ H ₂₄ N ₂ O	47	176-178	ET	C, H, N

^a No attempts were made to optimize yields. ^b ET, Et₂O. ^c Analyses for elements were within ±0.4% of the theoretical values. ^d Yield given for the chromatographic isolation on alumina. ^e The compound was an oil.

Table IV. Basic Derivatives of 6,7-Dihydroindolo[1,7-*ab*][1]benzazepine (28-39) and 6*H*-Indolo[7,1-*cd*][1,5]benzoxazepine (26, 27)

<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>26, 27</p> </div> <div style="text-align: center;">  <p>28-36</p> </div> <div style="text-align: center;">  <p>37-39</p> </div> </div>										
No.	Y	Z	n	R ₁	R ₂	Formula	Yield, % ^a	Mp, °C	Crystn solvent ^b	Analyses ^c
26	Me					C ₂₀ H ₂₂ N ₂ O·HCl	44	183-185 ^d	M-ET	C, H, Cl, N
27	H					C ₁₉ H ₂₀ N ₂ O·HCl	70	209-211	M-ET	C, H, Cl, N
28	H		1	Me	Me	C ₂₀ H ₂₂ N ₂	92 ^e	^f		^g
29	H		1	Me	PhCH ₂	C ₂₆ H ₂₆ N ₂ ·HCl	77	201-203	M-ET	C, H, Cl, N
30	H		1	PhCH ₂	PhCH ₂	C ₃₂ H ₃₀ N ₂ ·HCl	53	197-199	E-ET	C, H, Cl, N
31	H		1	Me	H	C ₁₉ H ₂₀ N ₂ ·HCl	76	200-202	M-ET	C, H, Cl, N
32	Me		1	Me	Me	C ₂₁ H ₂₄ N ₂	60 ^e	^h		ⁱ
33	Me		1	Me	PhCH ₂	C ₂₇ H ₂₈ N ₂ ·HCl	38	199-201	M-ET	C, H, Cl, N
34	Me		1	Me	H	C ₂₀ H ₂₂ N ₂ ·HCl	87	204-206	M-ET	C, H, Cl, N
35	H		0	Me	Me	C ₁₉ H ₂₀ N ₂	83	74-76	ET	^j
36	Ph		1	Me	Me	C ₂₆ H ₂₆ N ₂	50	156-158	ET	C, H, N
37		H				C ₁₉ H ₂₀ N ₂ ·HCl	67	133-135 ^{k,l}	W	C, H, Cl, N
38		Me				C ₂₀ H ₂₂ N ₂	51 ^e	^m		ⁿ
39		Ph				C ₂₅ H ₂₄ N ₂	48	139-140	M	C, H, N

^a No attempts were made to optimize yields. ^b M, MeOH; ET, Et₂O; E, EtOH; W, H₂O. ^c Analyses for elements were within ±0.4% of the theoretical values. ^d Free base, mp 93-95° (petroleum ether): NMR δ 2.30 (s, 1, CH₃-2). ^e Yield given for the chromatographic isolation on alumina. ^f The compound was an oil. ^g Characterized as the methiodide, mp 190-192° (ethanol). Anal. (C₂₁H₂₅IN₂) C, H, N. ^h The free base was an oil. ⁱ Characterized as the methiodide, mp 168-170° (ethanol). Anal. (C₂₂H₂₇IN₂) C, H, N. ^j Characterized as the methiodide, mp 265-267° (ethanol). Anal. (C₂₀H₂₃IN₂) C, H, N. ^k Lit.² mp 135-137°. ^l Free base, mp 67-69° (cyclohexane): NMR δ 7.45-6.85 (m, 8, Ar H and H-1). ^m The free base was an oil: NMR δ 2.50 (s, 3, CH₃-1). ⁿ Characterized as the methiodide, mp 258-260° (ethanol). Anal. (C₂₁H₂₅IN₂) C, H, N.

Table V. Pharmacological Data

No.	Reserpine antagonism		Antispasmodic activity in vitro		Acute toxicity, LD ₅₀ , ^b mg/kg po
	Ptois prevention, MED, ^a mg/kg po	Hypothermia reversal, MED, ^a mg/kg po	Antihistaminic act., ED ₅₀ , μg/ml	Anticholinergic act., ED ₅₀ , μg/ml	
26	10	>50	NT ^c	NT ^c	310 (221-434)
27	3	50	1	10	195 (156-244)
28	2	5	0.2	1	420 (258-685)
29	3.5	5	>5 ^d	>5 ^d	>4000
30	50	>50	>10	>10	1400 (833-2350)
31	1	2.5	0.6	4	410 (259-648)
32	7.5	>50	>10	>10	195 (129-294)
33	>50	>50	NT	NT	>4000
34	2.5	>50	5	6	390 (312-488)
35	>50	>50	NT	NT	210 (140-315)
36	>50	>50	NT	NT	1900 (1265-2850)
37	>50	>50	NT	NT	170 (94-305)
38	>50	>50	NT	NT	450 (265-765)
39	>50	>50	NT	NT	1600 (936-2730)
Imipramine	2.5	2.5	0.006	0.3	410 (284-595)

^a MED = approximate median effective dose derived as explained in the Experimental Section. ^b 95% confidence limits of LD₅₀ are reported in parentheses. ^c NT = not tested. ^d Compound insoluble at higher concentrations.

Compounds 35 and 36 of Table IV were synthesized by the procedure shown in Scheme IV. Hydrolysis of the esters 5 and 11 followed by condensation of the corresponding acid chlorides with dimethylamine,¹³ afforded the amides 24 and 25. Reduction of 24 and 25 with lithium aluminum hydride in refluxing ethyl ether gave 35 and 36.

Results and Discussion


All the compounds listed in Table IV were evaluated for the antidepressant activity using the antagonism to the reserpine-induced ptosis and hypothermia tests. The results are listed in Table V wherein the antispasmodic activity in vitro and the acute toxicity are also reported.

The amino derivatives 26-29, 31, 32, and 34 were able

to inhibit reserpine-induced ptosis, showing various degrees of potency. Three of these compounds (28, 29, and 31) were also active in reversing reserpine-induced hypothermia. All the compounds tested for antispasmodic activity were less active than imipramine as acetylcholine and histamine antagonists. The observation of animals for gross symptomatology revealed no prominent behavioral changes indicative of CNS stimulation or depression, clonic convulsions appearing at lethal doses only.

The results of the antireserpine tests revealed some interesting aspects of the structure-activity relationships of these compounds. Mono- or disubstituted aminoalkyl groups at C-1 of 6,7-dihydroindolo[1,7-*ab*][1]benzazepine (I) are necessary for the antidepressant activity as illus-

Scheme IV



trated by the comparison of 28 and 37. The inactivity of 35 indicates that the separation of the amino group from the nitrogen atom in structure I by three carbons is important for antireserpine activity. Substituents at C-2 resulted in reduction or elimination of activity. In particular, the substitution of a methyl group at C-2 of 29 was found to completely abolish the antidepressant activity (33).

As far as the amino group substituents are concerned, the monomethyl compound 31 displayed higher antireserpine activity than the corresponding dimethyl-substituted 28. Replacement of both methyl groups of 28 by benzyl groups (30) completely abolished its activity, while replacement of only one methyl group of 28 with a benzyl group (29) reduced its acute toxicity without a corresponding decrease in antireserpine activity. Compound 29 compared favorably with imipramine in terms of the toxicity-activity ratio. The introduction of an oxygen atom into the ethylene bridge (26 and 27) did not improve the antidepressant activity of 32 and 28.

Owing to these screening results, 29 and 31 showed the best activity profiles and were selected for further investigation.

Preliminary pharmacological results showed that these two compounds are devoid of anti-MAO activity as revealed by the absence of potentiation of tryptamine symptomatology in the rat.¹⁴ The same compounds were unable to antagonize the convulsions induced by pentylenetetrazole¹⁵ or strichnine¹⁶ and to interfere with the motor coordination in mice as assessed by the performance on the rotating rod test.¹⁷ Furthermore, 29 was as active as imipramine in antagonizing serotonin-induced contraction of the isolated guinea-pig ileum.¹⁸

Experimental Section

Synthetic Procedures. Melting points were taken in open capillary tubes using a Tottoli apparatus (N. Büchi, Flawil, Switzerland) and are uncorrected. Where analyses are indicated only by symbols of the elements, analytical results obtained for these elements were within $\pm 0.4\%$ of the theoretical values. All intermediates and final products were checked by ir and NMR spectroscopy (Perkin-Elmer 257 and Varian T-60A, respectively) and their spectra were found to be in agreement with the assigned structures. Ir and NMR spectra were obtained for KBr disks and for solutions in CDCl_3 (Me_4Si), respectively. Thin-layer chromatograms were prepared using silica gel 60F-254 plates from E. Merck, Germany. "Alumina" refers to neutral Al_2O_3 B III from E. Merck, Germany. "Florisil" refers to magnesium silicates (100–200 mesh) from Floridin Co., Pa.

5,11-Dihydro-5-nitrosodibenz[*b,e*][1,4]oxazepine (2). To a mixture of 3.94 g (0.02 mol) of 1 and 1.52 g (0.022 mol) of NaNO_2 in 40 ml of DMF, 20 ml of 2 *N* HCl was added slowly under stirring

at 5°. The cooling bath was then removed and stirring continued for 1 hr. The mixture was poured into water; the solid was filtered off, washed, and dried to yield 4.2 g of 2 (93%), mp 96–98°. Anal. ($\text{C}_{13}\text{H}_{10}\text{N}_2\text{O}_2$) C, H, N.

5-Amino-5,11-dihydrodibenz[*b,e*][1,4]oxazepine Hydrochloride (3). A mixture of 8.43 g (0.129 g-atom) of Zn dust and 15 ml of water was stirred vigorously at 10° while a solution of 6.78 g (0.03 mol) of 2 in 6.8 ml of glacial AcOH and 200 ml of EtOH was added in a slow stream at 20°. The mixture was stirred for 10 min at room temperature. The solution was filtered from the unreacted Zn and evaporated to dryness under reduced pressure. The residue was treated with 10% NH_4OH and extracted with Et_2O . The resulting solution was dried (Na_2SO_4), cooled, and treated with 2 *N* HCl under N_2 . The precipitate was filtered off, washed with Et_2O , and dried in vacuo to yield 4.6 g (62%) of 3 (green), mp 120° dec. Anal. ($\text{C}_{13}\text{H}_{13}\text{N}_2\text{OCl}$) C, H, Cl, N.

6*H*-Indolo[7,1-*cd*][1,5]benzoxazepine-1-carboxylic Acid Ethyl Ester (6) and 7*H*-Indolo[1,7-*ab*][4,1]benzoxazepine-1-carboxylic Acid Ethyl Ester (13) (Table I, 5–13). A mixture of 11.94 g (0.048 mol) of 3 and 6.15 g (0.053 mol) of MeCOCOOEt in 450 ml of EtOH was refluxed for 0.5 hr with stirring. To the hot solution 50 ml of 3 *N* ethanolic HCl was added and the whole mixture was then heated under reflux for 0.5 hr. The mixture was cooled, NH_4Cl was filtered off, the solution was evaporated to dryness, and the crude material was extracted with CHCl_3 . The organic phase was washed neutral with water, dried (Na_2SO_4), and evaporated under reduced pressure to give 12.6 g of crude oil. NMR indicated a 4:1 mixture of isomers 6 and 13. After column chromatography on alumina (ratio 1:50) using C_6H_6 -cyclohexane (1:1) as eluent and recrystallization from petroleum ether, 5 g of 6 [mp 76–78°; NMR δ 7.55 (dd, 1, J = 7 and 3 Hz, H-3), 7.45 (s, 1, H-2), and 5.25 (s, 2, OCH_2)] and 1.4 g of 13 [mp 125–127°; NMR δ 7.45 (s, 1, H-2), 7.40 (dd, 1, J = 7 and 3 Hz, H-3), and 5.30 (s, 2, CH_2O)] were obtained.

6,7-Dihydroindolo[1,7-*ab*][1]benzazepine (Table I, 14). A mixture of 2.9 g (0.011 mol) of the acid 15, 25 ml of quinoline, and 0.30 g (0.003 mol) of CuCl was heated at 225° for 2 hr. The mixture was cooled and poured into ice-water. The resulting mixture was made neutral with 2 *N* HCl and then extracted with CHCl_3 . The CHCl_3 solution was washed with water, dried (Na_2SO_4), and evaporated under reduced pressure to dryness. The residue was purified by column chromatography on alumina (ratio 1:30) using cyclohexane- CHCl_3 (9:4). The first component eluted was crystallized from EtOH to give 1.9 g of 14: mp 99–101° (lit.² mp 96–97°); NMR δ 7.55 (d, 1, J = 4 Hz, H-1) and 6.70 (d, 1, J = 4 Hz, H-2).

6,7-Dihydro-2-phenylindolo[1,7-*ab*][1]benzazepine-1-acetic Acid (17) (Table II, 15–17). A solution of 8.8 g (0.023 mol) of 11 in 100 ml of EtOH and 36 ml of 20% NaOH was refluxed for 2.5 hr. EtOH was removed in vacuo, and the solution was diluted with 50 ml of water and acidified with a slight excess of HCl. The precipitate was filtered, washed neutral with water, and dried in vacuo. Recrystallization from C_6H_6 -petroleum ether gave 5.3 g of 17, mp 192–194° dec.

2-Diazo-1-(6,7-dihydroindolo[1,7-*ab*][1]benzazepin-1-yl)-ethanone (18) (Table II, 18 and 19). A solution of 7.9 g (0.03 mol) of 15 and 11.9 g (0.1 mol) of SOCl_2 in 60 ml of dry C_6H_6 was refluxed for 3 hr. The solution was cooled and evaporated to dryness under reduced pressure. The residue was taken up in 150 ml of dry Et_2O and added to a solution of 5.9 g (0.14 mol) of CH_2N_2 in 270 ml of dry Et_2O at 5°. After 30 hr at 20–25°, the Et_2O was evaporated and the crude product was purified by column chromatography on Florisil (ratio 1:30) using C_6H_6 as eluent. The collected fractions gave 7.6 g of 18 which was used in the next step without further purification.

6,7-Dihydroindolo[1,7-*ab*][1]benzazepine-1-(*N*-benzyl-*N*-methylacetamide) (22) (Table III, 20–23). A mixture of 8.62 g (0.03 mol) of 18 and 145 g (1.2 mol) of PhCH_2NHMe in 1100 ml of EtOH was photolyzed (lamp 3500 Å) at 10–20° for 4 hr. The solution was evaporated to dryness and purified by column chromatography on alumina (ratio 1:50) using C_6H_6 as eluent. Evaporation of the first eluted component yielded 4.5 g of 22, homogeneous to TLC using CHCl_3 -MeOH (98:2). It showed ir absorption (1650 cm^{-1}) characteristic of an *N*-dialkylacetamide and was used without further purification in the next step.

6,7-Dihydro-2-phenylindolo[1,7-*ab*][1]benzazepine-1-(di-

methyacetylacetamide) (25) (Table III, 24 and 25). A solution of 14.13 g (0.04 mol) of 17 and 23.8 g (0.2 mol) of SOCl_2 in 350 ml of dry C_6H_6 was refluxed for 3 hr. The solvent was then evaporated to dryness under reduced pressure below 30° . The acid chloride residue was taken up in 150 ml of dry Et_2O . After filtration the resulting solution was added slowly to a solution of 9.02 g (0.2 mol) of Me_2NH in 12 ml of dry Et_2O . The reaction mixture was cooled to 5° and stirred for 30 min. The solid precipitate that formed was filtered and crystallized from Et_2O to give 7.2 g of 25, mp $176\text{--}178^\circ$.

1-[2-(Dimethylamino)ethyl]-6,7-dihydro-2-methylindolo[1,7-ab][1]benzazepine (32) (Table IV, 26, 32, 33, and 37-39). To 15 ml of glacial AcOH 3.7 ml of 33% aqueous Me_2NH solution (0.025 mol) was added with cooling and then 1.75 ml of 40% CH_2O solution (0.025 mol), followed by 4.2 g (0.017 mol) of 7. The mixture was stirred and refluxed for 2 hr and then poured into cold water. The aqueous portion was alkalized and extracted with Et_2O . The Et_2O solution was washed with water, dried (Na_2SO_4), and evaporated to yield a crude product which was purified by column chromatography on alumina (ratio 1:100) using C_6H_6 -petroleum ether as solvent. An amount of 3.1 g of 32 was obtained as a yellow oil [NMR δ 2.30 (s, 1, CH_3 -2)], which was converted to the methiodide, mp $168\text{--}170^\circ$, according to the procedure of Snyder et al.¹⁹

1-[2-(N-Benzyl-N-methylamino)ethyl]-6,7-dihydroindolo[1,7-ab][1]benzazepine Hydrochloride (29) (Table IV, 27-30, 35, and 36). A solution of 3.42 g (0.009 mol) of 22 in 25 ml of dry Et_2O was dropped into a suspension of 1.37 g (0.036 mol) of AlLiH_4 in 15 ml of dry Et_2O . The mixture was refluxed under stirring for 1 hr, cooled, and decomposed with water added at a rate so as to just maintain a gentle reflux of Et_2O . When all H_2 has been evolved, a slight excess of water was added and the mixture was stirred for 30 min at room temperature. The inorganic material was removed by filtration and washed with Et_2O . The Et_2O solution was dried (Na_2SO_4) and evaporated to give a crude oil. The residue was dissolved in 3 N ethanolic HCl and treated with Et_2O to give 2.8 g of 29. An analytical sample of 29 from $\text{MeOH-Et}_2\text{O}$ had mp $201\text{--}203^\circ$.

1-[2-(Methylamino)ethyl]-6,7-dihydroindolo[1,7-ab][1]benzazepine Hydrochloride (31) (Table IV, 31 and 34). A solution of 2.02 g (0.005 mol) of 29 in 200 ml of MeOH was hydrogenated for 23 hr over 0.700 g of 5% Pd on charcoal at 20° and 1 atm. The solution was filtered and evaporated to dryness under reduced pressure to give 1.2 g of 31. An analytical sample was obtained by recrystallization from $\text{MeOH-Et}_2\text{O}$, mp $200\text{--}202^\circ$.

Pharmacology. All the tests in vivo were conducted on male Swiss mice weighing 20-25 g. Five to ten animals were used at each dose level. All the compounds were administered orally, suspended or dissolved in 0.5% carboxymethylcellulose in a volume of 10 ml/kg of body weight, control animals receiving the vehicle alone. Reserpine was administered as "Serpasil" from Ciba, Switzerland.

Prevention of Reserpine-Induced Ptosis. The compounds were administered to mice at the screening dose of 50 mg/kg, 1 hr prior to reserpine (1.5 mg/kg iv). The degree of ptosis was measured by a scoring system according to Rubin et al.²⁰ The total score of a control group tested on the same day was expressed as 100 and the degree of antagonism by the test compounds as percentage. The compounds showing an inhibition of the control score higher than 50% at 50 mg/kg were tested at lower doses. The approximate MED (median effective dose), amount of drug in mg/kg necessary to antagonize the ptosis by 50%, was obtained by "eye-fit" linear plots on semilogarithmic paper.

Reversal of Reserpine-Induced Hypothermia. This test was carried out at room temperature of 20° according to the method of Askew²¹ with minor modifications. Mice were made hypothermic by reserpine and treated orally with the compounds at the screening dose of 50 mg/kg, 18 hr after reserpine injection (5 mg/kg ip). The compounds active at the screening dose were tested at lower doses.

Cumulative temperature values were obtained for control and treated groups by summing the values taken 1, 2, 3, and 5 hr after the compounds or saline injection. The drop of normal temperature in the reserpine-treated group was considered as 100. The dose able to reverse this reserpine-induced hypothermia by 50% (MED = median effective dose) was obtained, when possible, by graphical extrapolation from "eye-fit" linear plots on semi-logarithmic paper.

Antispasmodic Activity in Vitro. The test was carried out on isolated strips of ileum from male guinea pigs using 2.5×10^{-8} g/ml of acetylcholine or histamine as spasmogens. These agents were added to the Tyrode's solution maintained at 37° and oxygenated with 100% O_2 , 2 min following the addition of the test compounds. The compounds were dissolved in water or in 0.1 N HCl . The ED_{50} of each substance was obtained by graphical extrapolation from "eye-fit" linear plots of the results from at least three different preparations.

Acute Toxicity. All the compounds were administered orally to mice at not less than three dose levels. The rate of mortality was calculated on the seventh day after administration and the LD_{50} values were determined by the method of Litchfield and Wilcoxon.²² The animals were also observed for gross symptomatology at subtoxic doses.

References and Notes

- (1) A. Cañal-Rodríguez and P. R. Leeming, *J. Med. Chem.*, **15**, 762 (1972).
- (2) C. J. Cattanch, A. Cohen, and B. Heath-Brown, *J. Chem. Soc., Perkin Trans. 1*, 1041 (1973).
- (3) British Patent 1035450 (1966) issued to Roche Products Ltd. (July 6, 1966).
- (4) H. L. Yale and F. Sowinski, *J. Med. Chem.*, **7**, 609 (1964).
- (5) W. W. Hartman and L. J. Roll in "Organic Syntheses", Collect. Vol. II, A. H. Blatt, Ed., Wiley, New York, N.Y., 1943, pp 418-419.
- (6) J. A. Elvidge in "Nuclear Magnetic Resonance for Organic Chemists", D. W. Mathieson, Ed., Academic Press, London, 1967, pp 29-41.
- (7) W. A. Remers in "Indoles", Part I, W. J. Houlihan, Ed., Wiley, New York, N.Y., 1972, pp 1-226.
- (8) L. M. Jackman and S. Sternhell, Ed., "Applications of Nuclear Magnetic Resonance Spectroscopy in Organic Chemistry", 2nd ed, Pergamon Press, Oxford, 1969, pp 201-214, and references cited therein.
- (9) V. Snieckus and K. S. Bhandari, *Tetrahedron Lett.*, 3375 (1969).
- (10) B. B. Thompson, *J. Pharm. Sci.*, **57**, 715 (1968).
- (11) J. Thesing and G. Semler, *Justus Liebigs Ann. Chem.*, **680**, 52 (1964).
- (12) H. R. Snyder and C. W. Smith, *J. Am. Chem. Soc.*, **66**, 350 (1944).
- (13) W. B. Wright, Jr., and H. J. Brabander, *J. Med. Chem.*, **11**, 1164 (1968).
- (14) D. H. Tedeschi, R. E. Tedeschi, and E. J. Fellows, *J. Pharmacol. Exp. Ther.*, **126**, 223 (1959).
- (15) G. M. Everett and R. K. Richards, *J. Pharmacol. Exp. Ther.*, **81**, 402 (1944).
- (16) T. L. Kerley, A. B. Richards, R. W. Begley, B. E. Abreu, and L. C. Weaver, *J. Pharmacol. Exp. Ther.*, **132**, 360 (1961).
- (17) N. W. Dunham and T. S. Miya, *J. Am. Pharm. Assoc., Sci. Ed.*, **46**, 208 (1957).
- (18) R. D. Bunag and E. J. Walaszek, *J. Pharmacol. Exp. Ther.*, **136**, 59 (1962).
- (19) H. R. Snyder and P. L. Cook, *J. Am. Chem. Soc.*, **78**, 969 (1956).
- (20) B. Rubin, M. H. Malone, M. H. Waugh, and J. C. Burke, *J. Pharmacol. Exp. Ther.*, **120**, 125 (1957).
- (21) B. M. Askew, *Life Sci.*, **2**, 725 (1963).
- (22) J. T. Litchfield and F. Wilcoxon, *J. Pharmacol. Exp. Ther.*, **96**, 99 (1949).